This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.

开始日期2026-01-01

申办/合作机构

Ascendis Pharma A/S

NCT07345494

/ Not yet recruitingN/A

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

开始日期2026-01-01

申办/合作机构

Ascendis Pharma A/S

NCT07081997

/ Not yet recruiting临床3期

A Phase 3, Multicenter, Single Arm, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 µg/Day in Adult Participants With Hypoparathyroidism

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

开始日期2025-11-01

申办/合作机构

Ascendis Pharma Bone Diseases A/S

100 项与帕罗培特立帕肽相关的临床结果

登录后查看更多信息

100 项与帕罗培特立帕肽相关的转化医学

登录后查看更多信息

100 项与帕罗培特立帕肽相关的专利（医药）

登录后查看更多信息

6,466

项与帕罗培特立帕肽相关的文献（医药）

2026-03-01·JOURNAL OF THEORETICAL BIOLOGY

Can physical activity augment drug efficacy in PMO treatments - Insights from in-silico simulations of PTH and denosumab treatments

Article

作者: Pivonka, Peter ; Ruiz-Lozano, Rocío ; Calvo-Gallego, José Luis ; Martínez-Reina, Javier

The aetiology of osteoporosis (OP) is diverse, with ageing and the oestrogen decline after menopause being the main causes of the most prevalent type, primary OP. The concurrence of other diseases (such as chronic kidney disease or hyperparathyroidism), the use of certain medications (glucocorticoids) or an inadequate diet or a sedentary lifestyle may also cause or accelerate the appearance of OP. To counteract the sedentary lifestyle, physical exercise is often recommended as a preventive therapy or even as a complement to pharmacological treatments. In this work, we use a mathematical model of bone remodelling based on cell populations that implements bone mechanical feedback as a function of the strain level and the number of cycles of daily activities. We coupled this bone remodelling model with PK-PD models of denosumab and teriparatide to study the joint effect of drug treatments and exercise on bone density of postmenopausal women. Our results show that low-intensity exercise alone could slow down bone loss and prevent OP, particularly if started at a young age, and it could improve the efficacy of drug treatments, increasing bone density and reducing fracture risk. The incremental benefit of physical activity is greater in denosumab treatments, where the anabolic effect of exercise complements the anticatabolic effect of denosumab. However, the bone density gain and the reduction in fracture risk is greater, in absolute terms, in teriparatide treatments. In any case, disuse and sedentary lifestyle are detrimental to bone density and compromises the efficacy of drug treatments.

2026-03-01·Bioactive Materials

Programmed PTH pulsatility coupled with piezoelectric stimulation via ultrasound-activated scaffolds synergizes deep bone defect regeneration

Article

作者: Lian, Xiaofeng ; Zhang, Wei ; Wang, Xin ; Ding, Jianing ; Sun, Hui ; Shu, Linyuan ; Qi, Xin ; Liu, Chenjun ; Ge, Yuwei ; Yin, Bohao ; Guan, Junjie

Large bone defects in deep anatomical regions continue to pose significant clinical challenges for osteogenic reconstruction. While pulsatile low-dose parathyroid hormone (PTH) administration shows therapeutic potential for bone regeneration, its effective delivery to deep tissue defects remains problematic. To address this limitation, we developed a novel piezoelectric scaffold (KM@PTH) by integrating PTH with potassium sodium niobate (KNN)-mesoporous bioactive glass (MBG) composites. The KM@PTH system achieves synergistic deep bone regeneration by coupling ultrasound-activated piezoelectric stimulation with spatiotemporally programmed PTH pulsatility, where electromechanical microcurrents and biochemical signaling collaboratively enhance osteogenesis. This dual-modality approach initiates electrostatic PTH liberation while ultrasound-induced mechanical vibrations enhance protein release from the scaffold matrix. In a rabbit femoral defect model demonstrating deep tissue penetration capability, ultrasound-triggered pulsatile PTH delivery from KM@PTH significantly enhanced bone regeneration. Transcriptomic profiling identified calcium ion homeostasis as the central regulatory mechanism, elucidating the synergistic interplay between pulsatile PTH kinetics and electromechanical stimulation. The combined modality promoted osteogenesis through coordinated pathways: Enhanced calcium influx stimulating mitochondrial bioenergetics and mineralization; PKA/PKC-mediated upregulation of osteogenic factors; and mitochondrial functional activation coupled with inhibition of efferocytosis to enhance mesenchymal stem cell osteogenic commitment. This innovative integration of ultrasound-responsive piezoelectric systems with programmable drug release establishes a translatable paradigm for reconstructing challenging deep bone defects.

2026-03-01·BIOELECTROCHEMISTRY

Carbon nanotubes/polythiophene composite anodes: Fabrication and electrochemical energy storage performance

Article

作者: Duan, Guofeng ; Wang, Zhijie ; Wang, Yuyang ; Zhang, Dongming ; Chen, Yuchu ; Zuo, Jinlong ; Song, Yu ; Kong, Xiangquan ; Ma, Su

This study presents a significant advancement in a capacitive carbon felt/carbon nanotube/polythiophene (CF/CNT/PTh) bioanode. The CF framework provides mechanical stability. CNTs form a mesoporous structure (Barrett-Joyner-Halenda (BJH) pore volume: 0.016991 cm³/g), which supports increased populations of electroactive microorganisms. High-throughput sequencing confirmed a 6.67-fold increase in the relative abundance of electroactive genera. The key innovation of the CF/CNT/PTh is the incorporation of PTh to redesign the bioelectrochemical interface. The hydrophobic surface of PTh (confirmed by Fourier-transform infrared spectroscopy and Brunauer-Emmett-Teller analysis) reduces interfacial water barriers. Consequently, the charge-transfer resistance decreases by 65.3 % (R_ct = 2.80 Ω), as measured via electrochemical impedance spectroscopy. Additionally, the pseudocapacitive properties of PTh enable the storage of 5842.55C/m² of charge and generate a stronger bioelectric field (-578 mV open-circuit potential (OCP)), which enhances microbial activity. These effects create an "energy hub" in the bioanode, as stored and real-time electrons merge during discharge. Therefore, the CF/CNT/PTh bioanode achieves a current density of 147.925 A/m² and a power density of 1216.03 mW/m², which is 1.64 times that of bare CF. This design establishes a novel system through a microbial habitat environment constructed with CNT and a polythiophene-enhanced electron transfer mechanism, offering an innovative solution for micropower applications.

219

项与帕罗培特立帕肽相关的新闻（医药）

2026-01-15

·丁香园风湿时间

抗骨质疏松只知道地舒单抗？传统方案与新兴疗法超全总结

骨质疏松从来不是小病。在风湿免疫、内分泌、老年医学和骨科门诊，我们常见骨密度长期隐匿下降，最终以脆性骨折集中「爆雷」，带来功能丧失、再骨折和过早死亡等后果。到 2025 年，治疗已不再局限于「钙 + 维生素 D + 双膦酸盐」，多条通路的新药与序贯/联合策略推动治疗向个体化发展 [1]。一当前治疗格局：从经典到最新 01 抗骨吸收治疗（Antiresorptives）（1）双膦酸盐 [2] 双膦酸盐仍为多数情形下首选，代表药物包括阿仑膦酸盐、利塞膦酸盐、伊班膦酸盐和唑来膦酸等。其通过与骨羟基磷灰石结合，干扰破骨细胞的黏附、分化与存活，从而抑制骨吸收。口服制剂对胃肠耐受性有要求；对依从性差或有口服禁忌者，可选静脉唑来膦酸。长期用药需关注下颌骨坏死（MRONJ）和不典型股骨骨折（AFF），在用药 3~5 年后按个体风险评估是否考虑「drug holiday」。（2）地舒单抗（Denosumab）地舒单抗是抗-RANKL 人源化单抗，每 6 个月皮下注射一次，给药方便且降骨折风险显著，适用于不能耐受口服双膦酸盐或肾功能不全患者。地舒单抗不掺入骨基质，其作用可逆，停药后可能出现快速的骨量丢失与反跳性骨折，因此务必在停药前预先安排序贯抗骨吸收治疗以巩固效果，并需按期注射以避免「漏针」。使用时还需监测血钙，肾功能不全患者尤其需注意低钙的风险。（3）选择性雌激素受体调节剂（SERMs）代表药物雷洛昔芬，可在骨组织发挥类雌激素作用，降低椎体骨折风险的同时可降低乳腺癌风险，但其会增加静脉血栓风险并可能加重潮热等症状，适用时需权衡利弊，主要考虑于需兼顾乳腺肿瘤风险的绝经后女性。（4）激素替代治疗（HRT） HRT 在围绝经期或新绝经且合并明显更年期症状的女性既可缓解症状又能保护骨密度，但因可能增加乳腺癌、心血管事件与 VTE 风险，须严格个体化评估，不宜作为单纯骨保护的常规首选。（5）降钙素（Calcitonin）作用较弱，整体疗效不及上述药物，临床上多为无法耐受其他药物时的备选。 02 促成骨治疗（Anabolics）[3] 促成骨药物通过激活成骨通路直接增加新骨形成。特立帕肽（teriparatide，PTH 1-34）与阿巴帕肽（abaloparatide）均为间断给药的 PTH/PTHrP 类药，能在数月内显著提升成骨标志物并增加 BMD，适用于严重骨质疏松、既往脆性骨折或糖皮质激素所致骨质疏松等高危人群。临床上应将总疗程限定在 24 个月以内，疗程结束后必须立即序贯抗骨吸收药以巩固骨量增益并维持骨折风险降低。使用促成骨药需监测血钙并评估患者是否能配合随后的长期巩固治疗。 03 双重作用药物 Romosozumab[4] 为抗 sclerostin 单抗，具有同时促进成骨和抑制骨吸收的「双重作用」，在短期内对腰椎与髋部 BMD 的提升速度与幅度均较显著，适合骨折风险「非常高」的患者起始使用（例如近期脆性骨折或多发既往骨折、T ≤ −3.0 等）。Romosozumab 疗程通常限制为 12 个月，停用后需无缝接抗骨吸收药以维持获益。总体耐受性良好，但存在心血管事件增加的信号，既往 1 年内发生心肌梗死或脑卒中的患者禁用，心血管高危患者需谨慎评估。 04 联合与序贯治疗（1）联合治疗（同时用两种）理论上可利用促成骨与抗吸收药的互补机制以获得更快、更大 BMD 增益。临床研究显示【特立帕肽＋地舒】可在短期内显著提高腰椎与髋部 BMD，但【特立帕肽＋阿仑膦酸】未见叠加效果甚至可能抑制成骨反应。由于成本与管理复杂，联合治疗宜限于极高危或特殊病例。（2）序贯治疗（先后衔接用药）临床常用「先攻后守」策略：先用促成骨或 Romosozumab 快速建骨，随后紧接抗骨吸收药以维持增益。注意转换时机：长期口服双膦酸后再上促成骨，成骨反应可能减弱；由地舒直接转换为促成骨时髋部 BMD 可能短期下降，需个体化设计并密切监测。对近期骨折或 FRAX 高者，先促成骨 /Romosozumab 再接抗吸收药是当前证据支持的主要路径。 05 支持治疗钙以饮食为主，目标 1000-1200 mg/日；维生素 D 800-1000 IU/日（建议缺乏者补充，治疗前及治疗中应监测血清 25 羟维生素 D 水平）。避免常规大剂量钙补，且需结合心血管风险综合评估。运动以负重和抗阻训练为主，配合平衡训练与跌倒危险因素干预，按功能状态制定个体化方案。二炎症控制类生物制剂对骨的潜在益处炎症与骨丢失密切相关：促炎细胞因子（TNF-α、IL-1、IL-6、IL-17 等）可上调 RANKL，促进破骨。对风湿病人群而言，抗炎治疗常能改善骨转换标志物并在一定程度上稳定或小幅提升 BMD，但目前证据不足以将这些药物作为专门的防骨折药 [5]。 01 TNF-α 抑制剂（阿达木单抗、依那西普、英夫利昔单抗）可抑制炎症驱动的破骨过程。在类风湿关节炎等炎症性疾病中，使用 TNF 抑制剂后常见骨转换标志物下降和腰髋 BMD 稳定或略升。然而尚无确凿证据显示其能独立替代抗骨吸收或促成骨治疗以预防脆性骨折。 02 IL-6 抑制剂（托珠单抗）阻断 IL-6 信号可降低骨吸收相关标志物（如 CTX），临床上在活动期类风湿患者中常见腰髋 BMD 稳定或小幅增加，ACPA 阳性亚组效应更明显。当前证据仍以「炎症控制后附带获益」为主，独立降低骨折的证据不足。 03 T 细胞共刺激阻断（阿巴西普）通过抑制 T 细胞活化，阻断炎症级联的上游环节，间接影响 RANKL。真实世界队列提示阿巴西普对 BMD 的保护或优于部分对照，可能是合并骨质疏松风险的 RA 患者的合理治疗考量之一。 04 B 细胞清除抗体（利妥昔单抗） B 细胞对骨代谢的作用复杂，既能产生促破骨因子（如 RANKL），也能产生抗吸收因子（如 OPG）。达到良好炎症控制者可见 RANKL 下降与 BMD 稳定，但病情波动时效果不一致，主要收益仍来自对原发炎症的控制。 05 IL-17 抑制剂（赛库奇珠单抗）对脊柱关节病相关的局灶性骨破坏有保护潜力，系统性对抗骨质疏松的证据有限，临床上多表现为 BMD 稳定，作用更偏向控制局部炎性损害。 06 IL-23 抑制剂（ustekinumab、guselkumab、risankizumab）通过下游抑制 Th17/IL-17 轴间接控制炎症，针对全身骨代谢的临床数据稀少，护骨效果多被视为炎症控制的二次结果。 07 JAK 抑制剂（tofacitinib、baricitinib、upadacitinib、filgotinib）[6] JAK 抑制剂可同时阻断多种促炎细胞因子的信号。基础研究提示可能有利于成骨，但临床数据混杂：部分研究显示骨转换标志物改善，药物监测数据（如 VigiBase）亦提示骨折报告率的安全信号，需警惕并继续观察真实世界结局。 08 IL-1β（canakinumab）可降低骨吸收标志物，但临床证据有限，需更多研究确认对 BMD/骨折的实际益处。综上，对于风湿免疫病患者，有效控制原发病的炎症活动是保护骨健康的基础。在炎症控制达标后，若患者仍属骨折高危人群，应依据通用的骨质疏松治疗指南启动或优化抗骨质疏松治疗，而非仅依赖生物制剂的『附带』护骨作用。三正在开发的新型治疗 01 Wnt 通路调节剂：Sclerostin 与 DKK1 抑制剂 [7] Sclerostin 抑制剂除了罗莫苏单抗外，blosozumab 在临床早期也显示出希望，在一项 120 例的 II 期试验中，皮下给药 1 年使腰椎 BMD 增加 17.7%、全髋 6.7%，但其后开发被终止，具体原因未披露。 DKK1 也是 Wnt 的内源性抑制子，阻断其可促进成骨。但需注意，全身性增强 Wnt 信号存在潜在致瘤等安全顾虑。 02 Strontium ranelate[8] 口服可降低绝经后妇女骨折风险，兼具抑骨吸收与促成骨作用，但与心血管事件、VTE 和罕见严重过敏反应相关，因在多国未获批，临床应用极为有限。 03 Cathepsin K 抑制剂 [9] 以 odanacatib 为代表，LOFT III 试验显示每周给药可降低各类骨折并增加 BMD，但延长期观察到卒中事件增多，导致开发终止，其它同类药物亦因安全性问题未推进。 04 Calcilytics 口服小分子模拟间歇 PTH 的促成骨效应，动物与早期研究有积极信号（成骨标志物与 BMD 提升），但 II 期试验未显示显著 BMD 提高，开发受挫。 05 基于 PTH 的新策略在特立帕肽/阿巴帕肽基础上开发的新方向包括骨锚定（PTH-CBD）与长效前药（TransCon-PTH）等，目标是提高疗效与给药便利性 [10]。这些方案仍在临床验证阶段。 06 其他早期候选药物包括 AChE 抑制剂、降钙素受体激动剂、天然产物（如 tiliroside）、NLRP3/TLR4 等炎症相关靶点，以及 FAP、FGF21、SIRT3、P2X7、基因/细胞疗法等，多数证据来自动物或早期研究，作用与适应症尚不明确，安全性为主要限制。 07 临床开发亮点若干地舒单抗生物类似药已进入 II/III 期试验（如 CT-P41、RGB-14-P、QL1206、Bmab1000、AVT03、TVB-009 等），双特异性或新机制抗体（如同时抑制 sclerostin + DKK1 的 AGA2118）及改善给药方式的候选（如口服 PTH 类似物 EB613）在研。总体上，生物相似药可提升可及性，其它新药仍需更多抗骨折与安全数据支持。四总结当前骨质疏松治疗的核心不再是「有没有药」，而是把「风险识别 → 药物档位选择 → 序贯/接力设计 → 规范监测」形成临床流程。风湿科患者天然高风险，我们的价值就在于早期识别极高危患者、及时给予促成骨或双重作用起始并妥善安排后续巩固，从而最大限度减少脆性骨折的发生。 Take-home message 风险分层后再用药：极高危先促成骨或罗莫尤单抗，疗程后立即接抗吸收药巩固。药物安全性：Romosozumab 前评估心血管史；PTH 类/地舒单抗监测血钙；长期双膦酸盐注意 MRONJ 与 AFF。疗效监测：DXA 按药物调整频率；骨转换标志物可作为早期反应指标。地舒单抗停药管理：提前安排双膦酸盐接力，按时给药，防反跳性骨丢失和椎体骨折。基础治疗不可少：保证充足钙 + 维 D，常规推荐负重/抗阻训练。 ✩ 本文仅供医疗卫生等专业人士参考投稿邮箱：huanghaihua@dxy.cn 编辑：黄海花题图来源：站酷海洛参考资料： [1] Inderjeeth C, Inderjeeth DC. Novel therapies in osteoporosis - Clinical update - 2025. Best Pract Res Clin Rheumatol. Dec 2025;39(4):102100. doi:10.1016/j.berh.2025.102100 [2] Watts NB, Camacho PM, Lewiecki EM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. Apr 2021;27(4):379-380. doi:10.1016/j.eprac.2021.02.001 [3] Inderjeeth CA, Inderjeeth DC. The use of anabolic agents in the treatment of osteoporosis: a clinical update. Curr Opin Endocrinol Diabetes Obes. Aug 1 2024;31(4):157-163. doi:10.1097/med.0000000000000867 [4] McClung MR. Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res. Apr 2021;33(4):775-791. doi:10.1007/s40520-020-01708-8 [5] Kim Y, Kim GT. Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis. J Rheum Dis. Jan 1 2023;30(1):3-17. doi:10.4078/jrd.22.0046 [6] Martinez de la Torre A, Clausen AB, Burden AM, et al. Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase. Drug Saf. Feb 2025;48(2):191-201. doi:10.1007/s40264-024-01490-w [7] Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. Feb 2015;30(2):216-24. doi:10.1002/jbmr.2351 [8] Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. Jan 29 2004;350(5):459-68. doi:10.1056/NEJMoa022436 [9] McClung MR, O'Donoghue ML, Papapoulos SE, et al. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. Dec 2019;7(12):899-911. doi:10.1016/s2213-8587(19)30346-8 [10] Clarke BL, Khan AA, Rubin MR, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. Mar 17 2025;110(4):951-960. doi:10.1210/clinem/dgae693

2026-01-12

·BioSpace

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

- Rapidly transforming into a leading global biopharma company COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44 th Annual J.P. Morgan Healthcare Conference. “With our proven TransCon ® technology platform, strong R&D capabilities, and a maturing commercial infrastructure and financial profile, Ascendis is rapidly transforming into a leading global biopharma company,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “Over the next year, this inflection will be driven by further global penetration and commercial expansion, a third potential TransCon product approval with blockbuster potential, and an advancing R&D pipeline of highly differentiated internal and external TransCon product candidates, all of which create the foundation for sustainable long-term growth.” Selected Key Updates and Milestones TransCon PTH (palopegteriparatide, marketed as YORVIPATH ® ) YORVIPATH fourth-quarter 2025 and full-year 2025 unaudited preliminary revenue expected to be ~€187 million and ~€477 million, respectively. More than 5,300 unique U.S. patient enrollments, with nearly 2,400 unique prescribing healthcare providers at year end. Outside the U.S., now available commercially or through named patient programs in more than 30 countries, with full commercial launches anticipated in 10 additional countries by year end 2026. Confirmed product pro once-weekly TransCon PTH targeting patients receiving stable YORVIPATH doses. Ongoing label expansion trials through PaTHway60 (adults) and PaTHway Adolescent. TransCon hGH (lonapegsomatropin, marketed as SKYTROFA ® ) SKYTROFA fourth-quarter 2025 and full year 2025 unaudited preliminary revenue expected to be ~€53 million and ~€206 million, respectively. Received first label expansion in July 2025 with U.S. Food & Drug Administration (FDA) approval for adult growth hormone deficiency (GHD). Initiated Phase 3 basket trial for additional indications: idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA). TransCon CNP (navepegritide) In the U.S., PDUFA goal date of February 28, 2026 for pediatric achondroplasia. Submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) in October 2025, with a regulatory decision on potential use in pediatric achondroplasia anticipated in the fourth quarter of 2026. TransCon CNP + TransCon hGH Combination Therapy (navepegritide plus lonapegsomatropin) On January 8, 2026, announced Week 52 topline results from Phase 2 COACH Trial, which demonstrated improvements in annualized growth velocity (AGV) across both TransCon CNP treatment-naïve and TransCon CNP-treated children that exceeded the 97 th percentile of average stature children, along with improvements in body proportionality and arm span, and a safety pro with those observed for monotherapies of TransCon CNP and TransCon hGH. In Q4 2025, Ascendis submitted a protocol and held an end of Phase 2 meeting with the FDA regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia. Week 78 COACH data update anticipated in second quarter of 2026. Planned new trials to support TransCon CNP + TransCon hGH treatment in additional indications, such as hypochondroplasia. TransCon IL-2 β/γ (onvapegleukin alfa) Expect to report median overall survival (OS) data for a cohort of 70 patients with late-line platinum-resistant ovarian cancer (PROC) from the IL-Believe Trial of TransCon IL-2 β/γ + weekly paclitaxel in the second quarter of this year. Strategic Collaborations & Investments Novo Nordisk A/S Ongoing multi-product collaboration with Novo Nordisk for TransCon technology-based therapies in obesity and metabolic diseases. Lead program TransCon semaglutide remains on track to enter the clinic as anticipated. Eyconis, Inc. Ascendis has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and holds a 41% equity position in the company. Lead program TransCon aVEGF (EYC-0305) in development for wet AMD and other retinal diseases anticipated to enter the clinic in 2026. VISEN Pharmaceuticals Ascendis has granted VISEN Pharmaceuticals exclusive rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP in Greater China and maintains a 39% ownership interest in the public company. Biologic License Application (BLA) for TransCon hGH (lonapegsomatropin) as a potential treatment for pediatric growth hormone deficiency (PGHD) was accepted by China’s National Medical Products Administration (NMPA) in March 2024, with an approval decision anticipated in the first quarter of 2026. Teijin Limited Ascendis has granted Teijin Limited an exclusive license agreement for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for rare endocrinology diseases in Japan. In August 2025, YORVIPATH received MAA approval from Japan’s Ministry of Health, Labour, and Welfare. Financial Update Unaudited preliminary estimate of 2025 financial results: Total full-year 2025 product revenue of ~€683 million: YORVIPATH full-year 2025 revenue of ~€477 million SKYTROFA full-year 2025 revenue of ~€206 million Total full-year 2025 revenue of ~€720 million Full-year 2025 gross margin expected to be ~87% Total full-year 2025 operating expenses of ~€762 million December 31, 2025 unaudited preliminary cash balance of ~€616 million Expect operating cash flow of ~€500 million in 2026, based on current plans, exchange rates and excluding any contribution from TransCon CNP Planned $120 million share repurchase program in 2026 Share Repurchase Program The Board of Directors of Ascendis has authorized a $120 million Share Repurchase Program. Purchases under the Share Repurchase Program may be made from time to time through a variety of methods, which may include open-market purchases, privately negotiated transactions, or other methods permitted under applicable securities laws. The timing and amount of any repurchases pursuant to the Share Repurchase Program will be determined based on market conditions, share price and other factors. The Share Repurchase Program does not require Ascendis to repurchase any specific number of shares, and may be modified, suspended or terminated at any time without notice. Presentation at J.P. Morgan Healthcare Conference on Monday, January 12 A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at . The presentation will begin at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. A webcast replay will be available for 30 days. The Company’s slides from the J.P. Morgan presentation will be available on the same Investors & News website at . About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ potential to rapidly transform into a leading global biopharma company, (ii) anticipated commercial launches of TransCon PTH into additional countries, (iii) the PDUFA goal date of TransCon CNP for pediatric achondroplasia and EMA regulatory decision date on the potential use of TransCon CNP in pediatric achondroplasia, (iv) timing of week 78 COACH data and planned new trials to support TransCon CNP and TransCon hGH treatment in additional indications, (v) planned release of data from the IL-Believe Trial of TransCon IL-2 β/γ, (vi) clinical status of TransCon aVEGF, (vii) NMPA’s anticipated decision of TransCon hGH as a potential treatment for PGHD, (viii) the expected collaboration with Novo Nordisk and progress of TransCon semaglutide, (ix) expected full year 2025 SKYTROFA, YORVIPATH and total revenues, operating expense, cash balance and operating cash flow, (x) planned share repurchase program, (xi) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (xii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 12, 2025. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA ® , and YORVIPATH ® are trademarks owned by the Ascendis Pharma group. © January 2026 Ascendis Pharma A/S. Investor Contacts: Chad Fugere Ascendis Pharma ir@ascendispharma.com Media Contact: Melinda Baker Ascendis Pharma media@ascendispharma.com Patti Bank ICR Healthcare +1 (415) 513-1284 patti.bank@icrhealthcare.com

临床结果临床3期上市批准引进/卖出

2026-01-05

·生物制药合伙人

多肽长效药物侧链技术研究报告

多肽修饰种类繁多，从修饰位点不同则可分为N端修饰、C端修饰、侧链修饰、氨基酸修饰、骨架修饰等。作为一种改变肽链主链结构或侧链基团的重要手段，多肽修饰可有效改变肽类化合物的理化性质、增加水溶性、改变其生物分布状况、延长体内作用时间、降低毒副作用、消除免疫原性等。侧链修饰是最常用的长效修饰方法。多肽复杂侧链修饰是指对多肽分子中氨基酸侧链的功能基团进行选择性化学改造，以调控其物理化学性质、生物活性或功能特性。这一策略在多肽药物开发、分子探针设计及功能材料构建中至关重要，尤其适用于天然多肽存在稳定性差、半衰期短或靶向性不足等局限时。‌ 第一章长效多肽药物侧链的作用机理 ‌1. 药效动力学调控机制‌ 多肽长效化侧链通过延缓药物代谢与排泄，显著延长血浆半衰期。例如，脂肪酸侧链可促进药物与血清白蛋白结合，形成“储库效应”，使药物释放周期从数小时延长至数周‌。聚乙二醇（PEG）侧链通过增大分子量减少肾小球滤过率，同时形成空间位阻降低酶解速率‌。 ‌2. 分子稳定性增强路径‌ 侧链修饰可抑制多肽分子构象变化：‌多肽侧链修饰通过引入化学基团改变侧链性质，从而抑制构象变化，增强结构稳定性。其机理主要涉及‌空间位阻效应、稳定关键相互作用和引入共价约束‌。 ‌空间位阻效应‌：修饰基团（如聚乙二醇或脂肪酸链）引入后占据空间，阻碍主链旋转或侧链摆动，限制构象自由度，例如脂肽修饰通过疏水链增强分子内相互作用减少无序波动。 ‌ 稳定氢键网络或疏水核心‌：修饰如磷酸酯或糖基化可优化侧链极性，增强分子内氢键或疏水堆积，维持折叠状态，例如糖肽修饰通过水化层稳定二级结构。 ‌ 形成共价约束‌：如二硫键或环化修饰，直接连接侧链或末端，固定空间取向，例如侧链-侧链环化通过酰胺键锁定β-折叠或α-螺旋构象。‌ 3 靶向递送优化机制‌ 功能化侧链可赋予多肽组织特异性：‌ pH响应型侧链‌：在肿瘤微酸性环境中触发构象变化，实现局部药物释放‌；抗体片段偶联侧链‌：利用抗原-抗体结合实现靶向递送（如GLP-1受体激动剂与抗体Fc段融合）‌。第二章长效侧链主要类型与技术特性多肽侧链修饰主要针对特定氨基酸残基的反应性基团，包括： ‌赖氨酸（Lys）侧链‌：其ε-氨基是常见修饰位点，可通过酰化反应引入乙酰基、烷基或聚乙二醇链（PEG），以降低等电点、增强抗蛋白酶降解能力或延长半衰期；例如，生物素化可利用NHS-生物素试剂实现靶点捕获，而磺酰化则可能增强与靶蛋白的氢键相互作用。 ‌天冬氨酸（Asp）和谷氨酸（Glu）侧链‌：羧基可通过酯化或酰胺化调节多肽的亲疏水平衡，如甲酯化可提升脂溶性以促进细胞渗透，而乙醇胺酰胺化则可能改善水溶性。 ‌酪氨酸（Tyr）侧链‌：酚羟基的修饰包括磷酸化（模拟信号转导中的天然修饰）或碘标记（用于放射性成像）。 ‌半胱氨酸（Cys）侧链‌：巯基具有高反应活性，常用于二硫键形成或点击化学（如叠氮-炔环加成），以构建环状结构或引入荧光基团。‌ ‌1.化学修饰类侧链类型代表分子作用特点典型药物案例‌脂肪酸链‌ 棕榈酸、硬脂酸增强白蛋白结合能力索马鲁肽（司美格鲁肽）‌‌聚乙二醇‌ PEG2000-PEG4000 延长循环半衰期，降低免疫原性 PEG化干扰素α‌‌糖基化链‌ 甘露糖、唾液酸提升溶解性，增强淋巴系统靶向糖基化GLP-1类似物‌ 2. 生物偶联类侧链‌‌ Fc融合蛋白‌：将多肽与IgG抗体Fc段连接，利用新生儿Fc受体（FcRn）循环机制延长半衰期（如阿必鲁肽）‌；‌ 白蛋白结合域‌：通过基因工程融合白蛋白结合肽（如AlbudAb），使药物-白蛋白复合物半衰期达20-30天‌。 ‌3 .智能响应型侧链‌‌ 酶切响应链‌：在特定蛋白酶（如肿瘤微环境MMP-2）作用下释放活性药物，减少全身毒性‌；‌ ROS敏感链‌：在炎症部位高活性氧（ROS）环境下断裂，实现精准释药‌。长期大量供应各种多肽固相合成树脂：如2-CTC树脂，wang树脂，Rink 酰胺树脂 AM(氨甲基树脂），Sieber 树脂等，同时供应各种多肽、重组蛋白、抗体纯化填料，纯化工艺开发。联系：15771973009（微信同）。第三章技术发展趋势与市场前景 ‌1. 技术创新方向‌‌ 超长半衰期设计‌：多肽药物的超长半衰期设计旨在通过多种策略延长其在体内的循环时间，以减少给药频率并提高治疗便利性。核心原理是通过增加分子量、增强稳定性或改变分布特性来减缓肾脏清除和酶解降解。‌开发双重修饰侧链（如PEG-脂肪酸杂化链），目标将给药间隔延长至3-6个月‌；‌其中‌聚乙二醇化‌通过将聚乙二醇（PEG）链共价连接到多肽上，显著增大其水动力学体积，从而降低肾小球滤过率并形成空间位阻保护药物免受酶解；例如，长效生长激素和Palopegteriparatid（Yorvipath®）均采用此技术实现每周或更长给药间隔。此外，‌脂肪酸侧链修饰‌可引入疏水性基团（如地特胰岛素中的豆蔻酸），使其与血清白蛋白可逆结合，利用白蛋白的长半衰期（约19天）延长多肽滞留时间，但需平衡溶解度与结合亲和力以避免非特异性效应。‌ 口服递送突破‌：口服司美格鲁肽是代表性成功案例，其通过SNAC（N-[8-(2-羟基苯甲酰基)-氨基]辛酸钠）实现高效口服吸收，SNAC的作用机制包括：中和胃酸、保护药物免受胃蛋白酶降解；促进分子解聚（从多聚体转变为单体）以提升渗透性；以及调控膜流动性增强跨细胞转运；临床数据显示口服制剂吸收迅速（约1小时），且通过剂量滴定可实现显著疗效（如HbA1c降低约2%）。‌ 通过化学修饰增强多肽的稳定性和渗透性，例如脂肪酸酰化修饰（如司美格鲁肽和利拉鲁肽）在多肽链上引入脂肪酸侧链，使其与白蛋白可逆结合，从而延长半衰期、躲避酶解并增加脂溶性，促进跨膜转运；同时，分子量控制（如使用短链多肽）或结构稳定性提升（如环化）也有助于改善口服生物利用度。‌ 通过化学修饰增强多肽的稳定性和渗透性，例如脂肪酸酰化修饰（如司美格鲁肽和利拉鲁肽）在多肽链上引入脂肪酸侧链，使其与白蛋白可逆结合，从而延长半衰期、躲避酶解并增加脂溶性，促进跨膜转运；同时，分子量控制（如使用短链多肽）或结构稳定性提升（如环化）也有助于改善口服生物利用度。‌ AI驱动优化‌：利用深度学习预测侧链-多肽构效关系，缩短设计周期（从18个月压缩至6个月）‌。 ‌2.1 市场增长驱动因素‌‌ 慢性病需求激增‌：全球糖尿病患者超6亿，肥胖症患者达12亿，推动GLP-1类药物年需求增长23%‌；‌ 专利到期潮‌：2026-2030年将有17款重磅多肽药物专利到期，催生侧链改良型仿制药市场（预计规模180亿美元）‌；‌ 新型适应症拓展‌：阿尔茨海默病、NASH治疗中多肽药物渗透率提升（2024年相关临床试验增加40%）‌。 ‌3. 2030年市场预测‌‌ 规模‌：全球长效多肽药物市场将突破900亿美元，侧链技术贡献值占比提升至75%‌；‌ 技术分布‌：智能响应型侧链市场份额将达28%，超越传统PEG修饰（25%）‌；‌ 区域格局‌：中国市场份额从15%增长至30%，成为最大仿制药供应基地‌。第四章多肽长效药物侧链技术瓶颈免疫原性控制‌：PEG侧链引发抗药物抗体（ADA）概率达12%，限制长期使用‌；‌PEG侧链作为外来大分子，可能通过T细胞非依赖性（Ti）途径激活B细胞，导致抗PEG IgM的快速产生，这种反应主要由PEG的重复表面抗原通过多价交联B细胞受体（BCR）启动，不依赖T细胞辅助，因此产生的抗体亲和力较低且短暂；然而，部分个体也可能通过T细胞依赖性（Td）途径产生高亲和力IgG类ADA，这涉及抗原呈递细胞摄取PEG后处理并呈递肽-MHC II复合物，激活滤泡辅助T细胞，进而促进B细胞分化为浆细胞和记忆B细胞，导致持久的ADA反应。‌ 大规模生产壁垒‌：固相多肽合成（SPPS）作为工业主流，适用于10-50个氨基酸的合成，但复杂侧链多肽（如含二硫键、环化结构或非天然氨基酸）的合成效率显著降低，副反应（如消旋化、交联）风险增加，且需要多轮重复的缩合、洗涤和去保护操作，自动化难度高；液相合成虽可减少试剂浪费，但载体对氨基酸载量低，不适合中长肽段的大规模生产；生物合成法（如发酵法）依赖宿主细胞表达，但复杂侧链的翻译后修饰（如糖基化或磷酸化）效率低，产物异质性高，难以精确控制。‌ 复杂侧链多肽通常需引入支链保护基团（如苄基或叔丁基），这些基团需在合成后期用强酸去除，但保护基的选择与脱保护条件（如酸性或碱性环境）需与侧链官能团兼容，否则易引发副反应；例如，Fmoc策略虽温和适用于多数侧链，但对酸敏感基团（如某些环状肽）可能不适用，而Boc策略则需优化酸性脱保护条件以避免骨架断裂。监管标准升级‌：FDA要求新型侧链提供10年以上安全性追踪数据，延长上市周期‌。参考资料：刘梦,于彭城,徐寒梅. 蛋白多肽类药物长效化技术研究进展[J]. 药学进展,2019,43(03):209-216. 免责声明：本微信文章中的信息仅供一般参考之用，部分内容摘自网络及AI生成，如有侵权联系删除。此公众号任何时候都不保证文中描述内容的可靠性，不可直接作为决策内容，生物制药合伙人不对任何主体因使用本文内容而导致的任何结果承担责任。公众号已建立“生物药工艺开发技术交流”微信群，添加小编微信514099167 加入，加微信时备注姓名-单位-岗位，非生物制药行业人员勿扰。生物制药合伙人扫码关注我们 ID：zpt_Partner W：514099167 分享，点赞，在看！为生物制药人三连击！

100 项与帕罗培特立帕肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H05AA	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲状旁腺功能减退症	欧盟	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	冰岛	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	列支敦士登	Ascendis Pharma Bone Diseases A/S	2023-11-17
甲状旁腺功能减退症	挪威	Ascendis Pharma Bone Diseases A/S	2023-11-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04701203 (PaTHway, Company_Website) 人工标引	临床3期	甲状旁腺功能减退症	73	Palopegteriparatide	顧廠醖鹽鏇壓蓋蓋鬱衊(膚鏇築築積遞鹽餘積觸) = 觸範廠糧範蓋鏇膚鬱醖餘艱獵糧壓夢襯醖觸構 (衊鹹構鑰獵鹹夢網獵窪 ) 更多	积极	2025-07-14
NCT04009291 (PaTH Forward, NEWS \| Corporate Publications) 人工标引	临床2期	甲状旁腺功能减退症	56	Palopegteriparatide	淵鑰鏇簾顧壓淵壓齋繭(範願鑰襯艱窪窪鹽積鹽) = 遞鏇觸廠鏇範憲選蓋壓簾窪壓遞製夢鹽構簾網 (膚餘網鹹淵鏇壓膚膚憲 ) 更多	积极	2025-05-18
NCT04701203 (PaTHway, CTgov)	临床3期	甲状旁腺功能减退症	84	TransCon PTH (TransCon PTH)	壓鑰鏇網顧簾願壓繭廠 = 選餘選齋顧齋顧夢築糧構窪淵獵顧鏇積鏇蓋選 (襯淵醖繭鏇齋範願鏇餘, 繭顧艱壓壓壓襯糧簾衊 ~ 醖簾製憲簾網壓鹹衊鹽) 更多	-	2025-02-28
				Placebo (Placebo)	壓鑰鏇網顧簾願壓繭廠 = 簾鹽鹽鬱願繭壓積鑰壓構窪淵獵顧鏇積鏇蓋選 (襯淵醖繭鏇齋範願鏇餘, 淵鑰願觸繭網範鏇繭醖 ~ 網窪齋網襯製遞憲鹽窪) 更多
NCT05387070 (PaTHway, PRNewswire) 人工标引	临床3期	甲状旁腺功能减退症	-	Palopegteriparatide	鑰夢鏇蓋齋簾夢餘鑰顧(顧壓鬱淵壓餘網憲鑰鏇) = 鹹窪艱範製築築遞膚衊醖選淵範齋製糧衊築鹽 (獵艱網範壓構壓築衊築 ) 更多	积极	2024-08-12
				Placebo	鑰夢鏇蓋齋簾夢餘鑰顧(顧壓鬱淵壓餘網憲鑰鏇) = 糧製醖鏇鹽願觸襯鬱觸醖選淵範齋製糧衊築鹽 (獵艱網範壓構壓築衊築 )
NCT04701203 (FDA_CDER) 人工标引	临床3期	甲状旁腺功能减退症	82	YORVIPATH	網壓繭窪鏇獵襯夢簾鬱(壓觸壓夢遞積鹽網獵廠) = 製願築膚齋廠夢範願願鏇製淵衊網壓積鏇選憲 (觸膚艱遞構夢簾鹽簾膚 ) 更多	积极	2024-08-09
				Placebo	網壓繭窪鏇獵襯夢簾鬱(壓觸壓夢遞積鹽網獵廠) = 窪構憲糧簾積築鹽鹽醖鏇製淵衊網壓積鏇選憲 (觸膚艱遞構夢簾鹽簾膚 ) 更多
NCT04701203 (PaTHway, Pubmed \| Adv Ther)	临床3期	甲状旁腺功能减退症	82	Palopegteriparatide	製襯鏇鹹積構築顧繭齋(顧憲夢積糧糧鹹觸觸襯) = One case of nephrolithiasis was reported for a participant in the placebo group during blinded treatment; none were reported through week 52 with palopegteriparatide 醖選窪顧窪選鏇齋衊繭 (蓋觸選艱鹽鬱鏇築膚淵 )	积极	2024-06-01
NCT04701203 (PaTHway, GlobeNewswire) 人工标引	临床3期	甲状旁腺功能减退症	82	TransCon PTH (palopegteriparatide)	鏇顧壓積獵艱築簾願鏇(淵觸顧顧膚製遞餘襯鬱) = 齋壓選獵遞遞遞鹹廠遞觸餘憲廠鏇鏇糧繭積窪 (壓艱鏇膚糧壓鏇齋鏇獵 ) 更多	积极	2024-05-13
				TransCon PTH (palopegteriparatide) (eGFR < 60 mL/min/1.73m2)	鏇顧壓積獵艱築簾願鏇(淵觸顧顧膚製遞餘襯鬱) = 襯願襯醖蓋餘願範築醖觸餘憲廠鏇鏇糧繭積窪 (壓艱鏇膚糧壓鏇齋鏇獵 ) 更多
NCT04009291 \| NCT04701203 \| NCT05387070 (PaTHway, ENDO2023)	临床3期	甲状旁腺功能减退症	82	TransCon PTH	憲顧遞願獵構餘憲獵艱(簾範遞醖遞積鬱齋遞齋) = trended toward norms from baseline to Weeks 26 and 52 鹹鬱鏇齋鑰繭鑰鹹壓築 (製觸齋鹹鹹餘觸鹽選鑰 ) 更多	积极	2023-10-05
NCT04009291 (PaTHway \| PaTH Forward, CTgov)	临床2期	甲状旁腺功能减退症	59	TransCon PTH (TransCon PTH 15 mcg)	廠範餘簾憲網顧網襯遞 = 選鹽鏇廠窪淵窪鑰網願簾窪衊窪窪廠窪獵鏇繭 (鏇衊網鑰壓鹹夢構鬱觸, 糧憲選獵觸蓋遞積窪淵 ~ 鏇鏇顧製膚選選簾淵構) 更多	-	2023-09-01
				TransCon PTH (TransCon PTH 18 mcg)	廠範餘簾憲網顧網襯遞 = 憲艱築蓋繭壓網淵築糧簾窪衊窪窪廠窪獵鏇繭 (鏇衊網鑰壓鹹夢構鬱觸, 顧鬱淵齋願構醖網淵醖 ~ 廠構製衊鏇鏇淵獵膚夢) 更多
PaTH Forward Trial (ENDO2022)	临床2期	甲状旁腺功能减退症	59	TransCon PTH 15 mcg/d	淵廠艱艱積鹹簾糧窪網(製築鏇夢網願製觸膚餘) = 鏇鑰艱壓鑰淵憲製廠願願繭簾窪鹹選鑰蓋觸鑰 (顧鹹構獵網積製淵構範 ) 更多	积极	2022-11-01
				TransCon PTH 18 mcg/d	淵廠艱艱積鹹簾糧窪網(製築鏇夢網願製觸膚餘) = 淵簾衊觸顧構願鏇廠繭願繭簾窪鹹選鑰蓋觸鑰 (顧鹹構獵網積製淵構範 ) 更多